Regentis Biomaterials Ltd (RGNT)
Regentis Biomaterials Ltd. is a healthcare company focused on regenerative medicine and tissue repair solutions. The company develops and commercializes products in the United States, including Gelrin, a hydrogel-based platform designed for the repair and regeneration of damaged or diseased tissue. Its pipeline also includes GelrinC, a cell-free, off-the-shelf hydrogel that is being evaluated in a Phase II clinical trial for cartilage injuries in the knee. Incorporated in 2004, Regentis Biomaterials is based in Herzliya, Israel, and its common stock is listed on the NYSE under the symbol RGNT.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-RGNT
|
$3.19
|
62.9% Upside
|
Bargain
|
$10
|
410.2% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
—
|
-0.7x
|
2.2x
|
—
|
10.359 M
|
4.022 M
|
10.4%
|
54.5%
|
-21.0
|
—
|
10.0%
|
